Navigation Links
Armune BioScience to Participate in MultiPlan’s Networks, Expanding Access to APIFINY
Date:4/5/2016

Armune BioScience, an emerging leader in cancer diagnostics, has recently completed a national Ancillary Service Agreement with MultiPlan, Inc.

Under the new Agreement, APIFINY® will participate in the PHCS Network, MultiPlan’s national primary network, the MultiPlan Network, MultiPlan’s national complementary network, and ValuePoint by MultiPlan®, a national discount card network used by individuals responsible for paying their own healthcare bills. MultiPlan is the nation’s oldest and largest supplier of independent, network based cost management solutions, with an estimated 68 million consumers accessing its networks.

Launched in the United States in April of 2015, APIFINY is the only cancer specific, non-PSA blood test available to aid clinicians in the risk assessment for the presence of prostate cancer. APIFINY order volume exceeded 5,000 tests in its first year on the market. Primary care physicians and urologists have utilized APIFINY to help move beyond PSA based testing to assess prostate cancer risk.

“We look forward to working with MultiPlan and making APIFINY available to their clients’ healthcare members. Securing a contract with MultiPlan is another example of the potential game-changing clinical and economic value that APIFINY offers,” said David A. Esposito, President and CEO of Armune BioScience. “Given the current concerns of PSA testing throughout the world, APIFINY is well positioned to offer clinicians additional information in the assessment of prostate cancer risk. In addition, we are confident that APIFINY will help to address our healthcare system’s demand for improved outcomes at lower costs.”

APIFINY was developed based on innovative research into the immune system’s response to cancer conducted at the University of Michigan. Armune is currently expanding testing throughout the United States and preparing to launch APIFINY in several markets worldwide. Armune recently retained Mavericks Capital as the company’s advisor and investment bank.

About MultiPlan ( http://www.multiplan.com)
MultiPlan, Inc. is the industry’s most comprehensive provider of healthcare cost management solutions. The company provides a single gateway to a host of network- and analytics-based solutions for managing the financial risks associated with healthcare claims as well as products that fight waste, abuse and fraud before payments are made. Clients include insurers, health plans, third party administrators, self-funded employers, HMOs and other entities that pay medical bills in the commercial healthcare, government, workers compensation and auto medical markets. MultiPlan is owned by an investment group led by Starr Investment Holdings and Partners Group.

About Mavericks Capital ( http://www.maverickscap.com)
Mavericks Capital LLC and its licensed broker dealer, Mavericks Capital Securities LLC, specializes in advising companies on M&A, capital raises and strategic partnerships across the healthcare sector. With a senior team having deep medical perspectives, core scientific knowledge and proprietary analytics, we help construct and facilitate innovative and lucrative solutions for our clients. Our practice areas include therapeutics, devices, diagnostics, services and digital health.

About Armune BioScience ( http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. Armune was incorporated as a Delaware Corporation in 2008 with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.

Read the full story at http://www.prweb.com/releases/2016/04/prweb13311606.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. Armune BioScience Expands Access to Apifiny with ARCpoint Labs
2. Armune BioScience Secures Contract for Apifiny with America's Choice Provider Network to Expand Access to Apifiny
3. Armune BioScience Expands Access to Apifiny in Key International Markets with Vantari International
4. Armune BioScience Expands Access to Apifiny with Accu Reference Medical Lab
5. Armune BioScience Announces Agreement Retaining Mavericks Capital as Advisor and Investment Bank
6. Armune BioScience, Inc. Announces the Appointment of Robert W. Reinhardt, MD as Chief Medical Officer
7. Armune BioScience, Inc. Announces Study Results Demonstrating Added Convenience of Apifiny
8. GD Biosciences Announces Availability of the PULs Cardiac Test in India as Part of International Expansion
9. Wayne State opens new $93 million biosciences center aimed at eliminating health disparities in Detroit
10. Sharp Edge Labs and Creagen Biosciences Enter Drug Discovery Collaboration
11. 21st Century Oncology Partners with University of Arizona’s Center for Applied Nanobioscience and Medicine in Phoenix to Advance Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... Jacksonville, Florida (PRWEB) , ... April 27, 2017 , ... ... qualified candidates. But they will rapidly reject an outdated healthcare executive resume. , “If ... good look at your executive resume and wondering if it’s as ready as you ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... North American CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication ... 60,000 North American professional caregivers for the prestigious award each year – identifying ...
(Date:4/27/2017)... ... ... Offering the purest product of its kind, Swissx Labs AG has launched ... the market has seen before. Swissx uses proprietary strains of hemp plants grown in ... for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. Learn ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an ... it has completed a round of funding to accelerate its growth strategies. The ... Granite Capital is a growth equity firm focused on investments in healthcare and ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: